Racial differences in health-related quality of life among hemodialysis patients  by Unruh, Mark et al.
Kidney International, Vol. 65 (2004), pp. 1482–1491
Racial differences in health-related quality of life among
hemodialysis patients
MARK UNRUH, DANA MISKULIN, GUOFEN YAN, RON D. HAYS, ROBERT BENZ, JOHN W. KUSEK,
KLEMENS B. MEYER, and THE HEMO STUDY GROUP
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Tufts-New England Medical Center, Boston, Massachusetts;
Cleveland Clinic Data Coordinating Center, Cleveland, Ohio; UCLA Department of Health Services, Los Angeles, California;
Lankenau Hospital, Wynnewood, Pennsylvania; and National Institute of Diabetes, Digestive and Kidney Diseases, Division of
Kidney, Urologic, and Hematologic Disease, Bethesda, Maryland
Racial differences in health-related quality of life among
hemodialysis patients.
Background. Despite technical progress in therapy,
hemodialysis patients continue to report health-related quality
of life (HRQOL) substantially lower than that of the general
population. While African Americans with end-stage renal
disease (ESRD) survive longer than members of other races,
few studies have compared the HRQOL of African Americans
with that of non-African Americans.
Methods. We examined differences in sociodemographic,
clinical, and HRQOL variables by race. A multiple regression
model assessed the extent to which race was associated with
differences in HRQOL scores after adjustment for sociodemo-
graphic and clinical variables. Racial differences in the rela-
tionship between comorbid disease severity and HRQOL were
explored.
Results. In adjusted models, African Americans had higher
scores in the Index of Well-Being and burden of kidney disease,
but lower scores in cognitive function (all P < 0.05). For scales
reflecting symptoms and effects of kidney disease, sleep quality,
and the Physical Component Summary, the fall in HRQOL with
increasing comorbidity was significantly greater in non-African
Americans (all P < 0.05). After adjustment, there were no racial
differences in scores on the Mental Component Summary, social
support, dialysis staff encouragement, or patient satisfaction.
Conclusion. To our knowledge, ESRD is the only chronic
illness for which African Americans report significantly better
psychologic well being and a lower burden of disease than non-
African Americans. Further research is needed to understand
whether these experiences affect health care utilization, med-
ical decision making, and patient survival. Clarification of the
reasons for race differences may suggest measures to improve
HRQOL for all patients with ESRD.
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African Americans bear a disproportionate burden of
end-stage renal disease (ESRD). They constitute almost
one third of treated ESRD patients, but only 13% of the
United States population [2]. After adjusting for age, gen-
der, and the primary cause of kidney disease, African
Americans treated by hemodialysis survive longer than
whites [3]. In addition, African Americans with ESRD
are less likely to be treated by peritoneal dialysis [4],
and less likely to be listed for kidney transplantation [5].
Whites withdraw from dialysis treatment more often than
African Americans [6]; some have suggested that this im-
plies that African Americans’ quality of life in ESRD is
better than whites’ [7].
Previous studies of racial differences in health-related
quality of life (HRQOL) in ESRD have had method-
ologic limitations and conflicting findings. A study of
older dialysis patients conducted in the late 1980s showed
that whites were more likely to report physical symp-
toms and dissatisfaction with their health than were
African Americans [8]. These findings are difficult to in-
terpret because standards of dialysis care have evolved
substantially since the data were collected; patients did
not receive erythropoietin therapy, the standard dialy-
sis dose was lower than current practice, and high-flux
membranes were not used. Erythropoietin use has sub-
sequently been associated with significant improvements
in health status, particularly in physical functioning and
energy [9]. Furthermore, the study assessed individual
symptoms rather than measuring HRQOL with accepted
instruments. A small study of 79 incident dialysis pa-
tients showed the mental well being of African Ameri-
cans to be similar to that previously reported for whites
[10]. However, the study population was entirely African
American, and one third had experienced dialysis for less
than one month. In a large observational study of 5167
patients, investigators have found African American re-
port higher QOL scores in Physical Component Sum-
mary, Mental Component Summary, and kidney disease
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summary [11]. However, this study used race and ethnic-
ity classified by the coordinator rather than race reported
by the patient, and it lacked a validated comorbidity as-
sessment. Indeed, other studies have also included only
African Americans [10, 12]. Yet others may have failed
to adjust adequately for case-mix differences [8, 13, 14].
In all of these studies, apparent HRQOL differences may
have been at least partly attributable to the lesser burden
of comorbid disease in African Americans with ESRD
[15].
The present study assesses the relationship between
baseline HRQOL scores and race among participants
in the Hemodialysis (HEMO) Study, a large multicen-
ter population that measured HRQOL using validated
instruments and assessed comorbidity and case-mix vari-
ables. We hypothesized that African American race
would be associated with a higher HRQOL after adjust-
ing for demographic, socioeconomic, center, patient case-
mix, and other treatment-related factors.
METHODS
Study design
The HEMO Study is a 15-center randomized clini-
cal trial of the effects of hemodialysis dose and mem-
brane flux on mortality and morbidity in patients treated
with chronic hemodialysis [16]. The primary end point is
all-cause mortality. Patient eligibility criteria and other
study design issues have been previously described [1,
17]. The Institutional Review Board at all the institutions
approved the study protocol, and written consent was
obtained from all study participants. At randomization,
1813 of 1846 study participants completed the survey. En-
rollment in the HEMO Study began in March, 1995, and
ended in December, 2001. We report a cross-sectional
analysis of responses to the Index of Well-Being (IWB)
and to the Kidney Disease Quality of Life-Long Form
(KDQOL-LF) at the time of randomization.
Data collection
Demographic information and clinical history were
collected through review of medical records and self-
reported questionnaires. The race of the respondent
was assessed by self-report and all those that were self-
described as white, Asian, American Indian/Alaskan Na-
tive, or other were collectively classified as non-African
American for this report. Clinical data including labo-
ratory measurements were obtained using standardized
protocols [16]. Comorbidity was assessed at baseline us-
ing the Index of Coexistent Disease (ICED) [4, 18, 19].
The ICED aggregates the presence and severity of 19
medical conditions and 11 physical impairments into 2
summary indices: the Index of Disease Severity (IDS)
and the Index of Physical Impairment (IPI) [18]. An al-
gorithm combining peak scores for the IDS and IPI de-
termined the final ICED score. ICED scores range from
0 to 3, with a higher score reflecting increasing disease
severity.
HRQOL instruments
The IWB consists of 10 bipolar items on which the pa-
tient indicates how one feels about life, and one bipolar
item asking how satisfied a patient currently feels about
one’s life. The range for the IWB is 2.1 (low well-being)
to 14.7 (high well-being). The IWB has been shown to be
reliable and valid in both ESRD and non-ESRD popula-
tions [20].
The KDQOL-LF assesses generic and kidney-disease
targeted HRQOL domains. The SF-36 is the generic core
of the KDQOL-LF. The SF-36 has been extensively eval-
uated both in the general population and the ESRD
population [21–29]. The SF-36 questions are grouped
into eight scales: physical functioning (10 items), role-
physical (4 items), bodily pain (2 items), general health (5
items), vitality (4 items), social functioning (2 items), role-
emotional (3 items), mental health (5 items) [26]. Two
component summary scores are derived from these eight
scales. The Physical Component Summary scale (PCS)
aggregates items from physical functioning, role-physical,
bodily pain, general health, vitality, and social function-
ing. The Mental Component Summary scale (MCS) ag-
gregates items from role-emotional, mental health, and
also includes elements of general health, vitality, and so-
cial functioning. In the general population, the mean for
each summary scale is 50 points, with a standard deviation
of 10 points [30].
The KDQOL family of survey instruments has been
widely used in dialysis studies [31–35]. KDQOL-LF in-
cludes a Symptoms/Problems scale (34 items) that as-
sesses the extent to which symptoms bother the subject,
such as dry itchy skin, thirst and hunger, pain in the joints
or back, muscle cramps or soreness, and clotting or other
problems with the access site [6]. The Effects of kidney
disease scale (20 items) measures the impact of kidney
failure on daily life with questions about restrictions on
fluid and dietary intake, work, travel, lifting, and personal
appearance. Burden of kidney disease (4 items) considers
the impact of kidney failure on the sense of accomplish-
ment and achievement. Social support (4 items) assesses
satisfaction with family and social life. Sleep (10 items) as-
sesses subjective sleep initiation and maintenance, as well
as daytime somnolence. Dialysis staff encouragement (6
items) measures the extent to which the dialysis staff en-
courages patients to be independent and to lead as nor-
mal a life as possible. Patient satisfaction (2 items) gauges
how well dialysis care meets expectations. Cognitive func-
tion (6 items) considers difficulty with memory and con-
centration. Because it had less than adequate internal
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consistency reliability, we excluded the KDQOL-LF so-
cial interaction scale from this analysis. The range of
scores for the dialysis-targeted scales was 0 to 100, with a
higher score reflecting better health.
Statistical analysis
Differences between African Americans and non-
African Americans were assessed in demographic vari-
ables (including race), socioeconomic, clinical and
laboratory variables, and HRQOL scores. Two sample
t tests were used for continuous variables (e.g., age),
and chi-square test was used for categorical variables
(e.g., ICED). Descriptive statistics (mean, standard de-
viation, response rate, and percentage of patients at
the floor or ceiling) were calculated for each HRQOL
scale, and internal consistency reliability was estimated
(data not shown) [36]. Scale scores were estimated using
the average of an individual’s non-missing items when
at least half of the items in a scale were completed
(non-missing).
The associations with HRQOL scales of demographic
variables (including race), socioeconomic, clinical and
laboratory variables were evaluated using linear regres-
sion. A separate regression model was created for each
scale of the HRQOL instrument. To explore the extent
to which racial differences in HRQOL are accounted for
by other case-mix factors, we constructed three multi-
variable models for each scale, sequentially adding ad-
ditional factors to adjust for potential confounders on
the relationships of race with HRQOL domains. Because
study center was highly correlated with race, we con-
sidered center a possible confounder and included it in
each of the multiple regression analyses [37]. Therefore,
the first model contained race, sex, age, and duration
of dialysis. In the second model, we included additional
socioeconomic variables (employment, education level,
self-administration of survey, number of those in house-
hold, marital status, tobacco use, disability, and insurance
status). The third model included additional comorbid
disease and laboratory parameters [ICED comorbidity
index, more than one hospitalization in the past year, di-
abetes as a cause of ESRD, equilibrated normalized pro-
tein catabolic rate (enPCR), serum albumin, hematocrit,
creatinine, phosphorus, and equilibrated Kt/V (eKt/V)].
The models accounted for factors significant at the P <
0.05 level and included a few variables that were non-
significant but thought to be clinically important (age,
years on dialysis, the number of individuals in the pa-
tient’s household, whether the patient was listed for trans-
plantation, and baseline eKt/V). We found that it was
unnecessary to adjust for flux when including center as a
variable, because membrane flux at baseline was strongly
correlated with center. The signs of the estimated coeffi-
cients and the R2 were examined for each model.
We examined interaction terms for two reasons. First,
because 56.3% of HEMO Study participants were female,
we tested for differential gender effects on scale scores.
Second, we hypothesized that the relationship between
race and HRQOL might vary with severity of illness.
Therefore, we examined interactions between the race
covariate and duration of dialysis, diabetes, ICED score,
whether the patient was working, and the number of hos-
pitalizations in the past year. All interaction terms were
tested in the full model for each scale. Because 12 quality-
of-life indices were investigated, a total of 72 interaction
tests were performed, thereby inflating the risk of a type
I error. In this context we present both the preplanned
overall analysis of the “main effect” of race, and then the
interactions and associated subgroup analyses that should
be interpreted with caution because of the risk of a type
I error with multiple hypotheses [38–40]. All significance
tests were two-tailed and a P value of less than or equal to
0.05 was considered statistically significant. All analyses
were performed with Unix SAS 6.12 (Cary, NC, USA).
RESULTS
HEMO Study patient characteristics
Of 1846 patients randomized in the HEMO Study,
1813 patients completed the HRQOL questionnaire at
baseline. The 33 patients who did not respond did not
speak either English or Spanish. Of the remaining 1813,
1156 were African Americans (65.76%), 598 were white
(33%), 32 were Asian (1.8%), 16 were unknown (0.88%),
and 11 were American Indian/Alaskan Native. Among
those classified as African American, eight were self-
designated as Hispanic (0.7%), and of the 657 classified as
non-African American (white, Asian, other, and Ameri-
can Indian/Alaskan Native), 99 were Hispanic (15.1%).
Among all of the participants in this study, the mean age
was 58 years, and 56% was female. The mean duration of
dialysis was 3.74 years, and mean eKt/V was 1.35. A ma-
jority had either diabetes (38%) or hypertension (33%)
as the cause of ESRD, and one third (33%) had severe
comorbidity as represented by an ICED score of 3.
Differences in baseline characteristics
Table 1 shows that African American patients were
more likely to be female, to have less than a high school
education, and to have a history of tobacco and alco-
hol use. African American participants were less likely
to be married, less likely to have had more than one
hospitalization in the past year, and their comorbid ill-
ness severity was significantly less. The mean enPCR,
hematocrit, and serum phosphate of African Americans
were lower, while the mean serum creatinine was higher.
African Americans were more likely to have been treated
Unruh et al: Race differences in quality of life among hemodialysis patients 1485
Table 1. Sociodemographic and clinical characteristics of African American and non-African American HEMO Study participants
African American Non-African American
Variable (N= 1156) (N = 657) P value
Demographic Age years 57.8 (13.1) 57.3 (15.5) 0.52
Female % 61.6 47.2 0.001
Duration of dialysis years 3.76 (4.2) 3.72 (4.7) 0.85
Socioeconomic and health Working % 9.5 15.4 0.001
behaviors
At least high school education % 56.9 70.7 0.001
Self-administer the survey % 58.7 63.5 0.044
Number in household 2.6 (1.6) 2.6 (1.6) 0.87
Listed for transplant % 19.7 19.7 0.99
Married/common law marriage % 30.3 53.4 0.001
Divorced/separated/widowed % 50.1 27.6
Single/never married 19.5 19.2
Tobacco (current) % 20.4 12.2 0.001
Alcohol (abuse) % 20 9.6 0.001
Receives disability % 53 40.6 0.001
Private insurance % 42.7 60.8 0.001
Severity of illness and Diabetes % 46.9 41.9 0.07
clinical factors
ICED (0–1) % 37.9 30.8 0.007
ICED 2 % 31.5 30.0
ICED 3 % 30.6 39.1
Hospitalized >1 in past year 38.2 46.3 0.001
enPCR .98 (.25) 1.05 (0.24) 0.0001
Albumin g/dL 3.61 (0.39) 3.64 (0.41) 0.14
Hematocrit % 33.3 (4.5) 34.0 (4.4) 0.0017
Creatinine mg/dL 10.7 (2.9) 9.4 (2.6) 0.0001
Phosphorus g/dL 5.65 (1.8) 6.0 (1.9) 0.0003
eKT/V 1.34 (0.22) 1.36 (2.2) 0.21
Table 2. Mean HRQOL scores of African American and non-African American HEMO Study participants
HRQOL Scale African Americans Non-African Americans P value
Generic domains Index of Well-Being 10.34 (3.1) 9.44 (2.6) 0.0001
Physical Component Summary Score 36.3 (9.8) 34.78 (10.5) 0.0037
Mental Component Summary Score 50.1 (11.0) 49.4 (10.8) 0.14
Dialysis targeted Symptoms 75.9 (14.1) 74.1 (13.9) 0.009
Effects of kidney disease 67.9 (21.0) 63.0 (20.5) 0.0001
Burden of kidney disease 53.0 (29.6) 46.3 (28.3) 0.0001
Cognitive function 74.6 (21.0) 76.8 (19.9) 0.03
Social support 66.8 (23.2) 67.0 (22.9) 0.82
Sleep 58.9 (22.12) 56.2 (21.9) 0.02
Dialysis staff encouragement 68.9 (17.0) 67.4 (17.3) 0.03
Patient satisfaction 67.2 (19.6) 72.8 (20.0) 0.0001
by high-flux dialysis before study entry (65% vs. 53%,
v 2 = 23.9, P < 0.0001).
Unadjusted differences in HRQOL by race
Table 2 shows that African American hemodialysis pa-
tients reported a substantially higher average quality of
life on the IWB, had significantly higher SF-36 Physical
Component Summary scores (indicating better physical
health), and better scores on the scales symptoms of kid-
ney disease, effects of kidney disease, burden of kidney
disease, and sleep. African American patients reported
slightly lower cognitive function. They were significantly
less satisfied with their care than non-African American
patients, but reported more dialysis staff encouragement.
Adjusted differences in HRQOL for African Americans
Table 3 shows that higher scores (better health) in the
domains of the IWB and burden of disease persist in
the African American group after adjustment for cen-
ter, demographic, socioeconomic, clinical factors, and
severity of comorbid illness. On the IWB, the differ-
ence between the two groups was reduced, but remained
statistically significant after adjustment (P = 0.013). Af-
ter adjustment for covariates, the differences in scores
measuring Physical Component Summary and symp-
toms and effects of kidney disease were reduced in
magnitude. Despite adjustment for observed differences
between groups, burden of kidney disease scores re-
mained significantly higher (lower burden) in the African
American group (P = 0.012), and cognitive function
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Table 3. Adjusted mean differences between HRQOL scores of
African American and non-African Americansa
Unadjusted Adjusted
HRQOL Scale differenceb difference
Index of Well-Being 0.9◦ 0.46 (0.18)c
Physical Component Summary score 1.49◦ 0.02 (0.97)
Mental Component Summary score 0.81 0.24 (0.72)
Symptoms 1.8d 1.2 (0.87)
Effects of kidney disease 4.9e 2.0 (1.3)
Burden of kidney disease 6.67e 4.6 (1.8)c
Cognitive function −2.2c −3.04 (1.29)c
Social support −0.24 0.51 (1.4)
Sleep 2.5c 0.9 (1.38)
Dialysis staff encouragement 1.9c 2.04 (1.1)
Patient satisfaction −5.65e −1.31 (1.22)
aAll adjusted models account for clinical center, age, sex, duration of dialysis,
employment, education level, self-administration of survey, number of those
in household, marital status, listed for transplantation, tobacco use, alcohol
abuse, disability and insurance status, ICED comorbidity index, more than one
hospitalization in the past year, diabetes, enPCR, serum albumin, hematocrit,
serum creatinine, serum phosphate, eKT/V, and positive scores mean better
quality of life in all domains.
bAfrican American minus non-African American scale score.
cP < 0.05.
dP < 0.01.◦
P < 0.001.
scores remained lower (more cognitive symptoms) in the
African American group (P = 0.019). Finally, significant
unadjusted differences in sleep, dialysis staff encourage-
ment, and patient satisfaction by race were reduced in
magnitude after adjustment for covariates. As discussed
in the subsequent section, interactions were found be-
tween the ICED score and race, although these are not
included in the Table 3 results. The Table 3 results, there-
fore, should be interpreted as the effects of race av-
eraged across comorbidity level for the HEMO Study
population.
Differences in adjusted HRQOL scores by race for level
of comorbidity
In several domains, the relationship between race and
quality of life was influenced by comorbidity. Figures 1
to 4 stratify the relationships between race and HRQOL
scores by comorbidity level in the fully adjusted model.
Figure 1 shows the racial differences in SF-36 Physical
Component Summary score for level of comorbidity (the
P value for race by comorbidity interaction was 0.003).
For those with mild and moderate comorbidity (ICED 0
to 2), there were no clinically meaningful differences in
PCS scores between African Americans and non-African
Americans. However, among those with severe comorbid
illnesses, African Americans perceived less physical dis-
ability as compared with non-African American. There
were also differential effects of race across ICED levels
for the symptoms score, effects score, and sleep scores.
As shown in Figures 2 to 4, for individuals with mild-
moderate comorbidity, there were no clinically mean-
ingful differences by race in the respective health status
domains. However, the different perception of disability
across racial groups becomes manifest among individuals
with severe comorbid disease. At ICED level 3, African
Americans perceived less disability in Physical Compos-
ite Score, symptoms, effects of kidney disease, and sleep
domains, as compared to non-African Americans.
As a sensitivity analysis, we examined the individual
scales that are components of the PCS and MCS. After ad-
justment for demographic, socioeconomic, center, patient
case-mix, and other treatment-related factors, the inter-
action of race and level of comorbidity was significant
in scales measuring physical functioning (P = 0.02), role-
physical (P = 0.02), general health (P = 0.002), and social
functioning (P = 0.047). Second, no consistent interac-
tions across HRQOL domains were found between race
and gender, duration of dialysis, diabetes, work status, or
number of hospitalizations. Third, because of the ethnic
heterogeneity of the non-African American group, we
repeated our analyses using only non-Hispanic African
Americans and non-Hispanic whites. The results from
these analyses did not materially differ from our original
findings. Some small differences were presumably related
to a loss of power resulting from exclusion of a num-
ber of subjects from the non-African American group.
However, our interpretation of the data was unchanged,
and we have chosen to present the more inclusive racial
groupings because of our limited sample size.
DISCUSSION
It is well known that African Americans who have
suffered chronic kidney failure survive longer than non-
African Americans [41]. Unfortunately, there has been
little exploration of possible racial differences in patient
experience, either in chronic kidney disease or in other
common disease states. The data reported here add two
important details to our understanding of race and kid-
ney failure. First, African Americans’ general psycho-
logic well being appears to be more preserved on chronic
hemodialysis treatment than non-African Americans’,
and African Americans appear to experience kidney
failure as relatively less of a burden than do non-
African Americans. However, African Americans re-
ported slightly more cognitive problems. Second, African
Americans seem to be less vulnerable to deterioration in
the quality of life as comorbidity worsens.
The finding that African Americans have significantly
better psychologic well being and that they experience
kidney disease as a smaller burden extends findings from
previous studies of race and HRQOL. These findings
are supported by a study using a two-item measure
of overall life satisfaction, adjusted for social support,
which found that African Americans with kidney fail-
ure reported greater overall life satisfaction than non-
African Americans. That study, however, did not adjust
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Fig. 1. Physical Composite Score (PCS)
among African American and non-African
Americans by level of comorbidity. Adjusted
PCS mean scores for African Americans and
non-African Americans by level of comorbid-
ity. African Americans’ PCS scores declined
less than non-African Americans’ scores, with
increasing levels of comorbidity (P = 0.003).
There were no substantial differences in PCS
scores in the mild to moderate levels of co-
morbidity. At the highest comorbidity level,
the African American mean adjusted PCS
score is 2.2 points higher than non-African
American.
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Fig. 2. Symptoms of kidney disease among
African American and non-African Ameri-
cans by level of comorbidity. Adjusted symp-
toms scores were significantly different for
African Americans and non-African Amer-
icans by level of comorbidity (P = 0.0015).
There were no substantial differences in
Symptom scores in the mild to moderate lev-
els of comorbidity. However, African Ameri-
cans in the third ICED group were 4.4 points
higher.
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Fig. 3. Effects of kidney disease among
African American and non-African Ameri-
cans by level of comorbidity. Adjusted mean
Effects scores for African Americans and
non-African Americans by level of comor-
bidity. As comorbidity level increases, non-
African Americans’ kidney disease effect
scores worsen significantly (P = 0.02) com-
pared to African Americans. There were no
substantial differences in Effects scores in the
mild to moderate levels of comorbidity. At the
highest level of comorbidity, African Amer-
icans’ Effects scores were 5.5 points higher
than non-African Americans.
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Fig. 4. Sleep quality among African Ameri-
can and non-African Americans by level of
comorbidity. Adjusted mean Sleep scores for
African Americans and non-African Amer-
icans by level of comorbidity. For individ-
uals with no to mild comorbidity, there
are no differences in sleep quality be-
tween African Americans and non-African
Americans. For those with intermediate
severity of comorbidity, African Americans
report lower sleep quality (2.3 points lower
than non-African Americans), but this re-
lationship reverses itself in those with the
highest grade of comorbidity, where sleep is
less disturbed in African Americans as com-
pared with non-African Americans (4.3 points
higher in African Americans vs. non-African
Americans).
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extensively for socioeconomic variables or comorbid-
ity [14]. The Dialysis Outcomes and Practice Patterns
(DOPPS) Study has reported black participants to have
a 1.3-point higher PCS and 1.1-point higher MCS than
whites [11], which were larger differences than we found
among our study population in the fully adjusted model.
Although the DOPPS analyses adjust for the presence of
a wide range of comorbidities, data characterizing sever-
ity of disease were limited in this study [42]. Because
disease severity varied across racial groups, inadequate
adjustment for comorbidity could affect the estimate of
the association between race and HRQOL, and explain
the differences between DOPPS and our fully adjusted
estimates for PCS and MCS. Our findings that mean MCS
scores did not vary significantly by race may be partly
explained by the circumstance that our population of
hemodialysis patients’ MCS scores was nearly the same as
those of the general population. Our finding that African
Americans reported a slightly lower cognitive function
score was not observed in the DOPPS results; we have no
explanation for this discrepancy except that the HEMO
Study used the KDQOL-LF and surveyed a different pa-
tient population. The KDQOL-LF has more items as-
sessing cognitive problems, and therefore may be slightly
more sensitive to differences than the KDQOL-SF cog-
nitive scale. Of the items measuring cognition measured
by the HEMO Study in the KDQOL-LF but not found in
the KDQOL-SF used by DOPPS, African Americans re-
ported significantly more problems with forgetting things
(v 2 = 30.2, P < 0.0001) compared to non-African Ameri-
cans. We speculate that this lower score in cognitive func-
tion may represent unobserved differences in education,
and the social and cultural influences on perception of
cognitive abilities.
Other authors who have observed racial differences
in HRQOL have speculated that differences in nutrition
might play a role [43, 44]. However, in adjusting for serum
albumin, creatinine, and enPCR, our analysis accounted
for much of the impact of nutrition [45]. Some authors
have suggested that racial differences in HRQOL may
reflect differences in social support [46]. In the present
cohort, however, no significant racial differences were re-
ported in social support. One can speculate that increased
knowledge of the impact of dialysis on daily life may play
a role in observed HRQOL differences of African Amer-
icans compared to non-African Americans. The strong
familial clustering of ESRD found in African Americans
with non-insulin dependent diabetes mellitus [47] may
mean that some of these patients have family with ESRD,
and are thus familiar with dialysis treatment. Experiences
within family or community may influence African Amer-
ican patients’ expectations. Some models of quality of life
[48] suggest that attenuated expectations may cause par-
ticipants to report relatively better well being and fewer
symptoms.
At higher levels of comorbidity, African Americans
reported better physical well being and fewer kidney
disease symptoms and effects than did non-African
Americans. These findings may be related to the im-
proved survival of African Americans on hemodialysis,
and to the lower likelihood of African Americans’ with-
drawal from dialysis therapy. This finding was previously
suggested by an apparently paradoxical relationship ob-
served in an African American hemodialysis cohort: as
severity of illness increased and objective function de-
creased, global satisfaction with life increased [12]. It
is possible that some of these perceived differences in
HRQOL for the sickest patients may be caused by racial
differences in religiosity [49]. Greater religiosity may lead
very ill patients to report fewer physical symptoms [50,
51]. A study in a largely African American hemodialy-
sis population showed that increased spirituality was sig-
nificantly associated with better quality of life [52]. In
addition, an assessment bias may account for these dif-
ferences, because an ethnic minority may be more skepti-
cal of a research study and health care and may withhold
more when reporting symptoms. However, in at least one
study, lack of trust could not be shown to predict ter-
minally ill African Americans’ reluctance to forgo life-
sustaining treatments [53]. Furthermore, the participants
in the HEMO Study trusted their health care providers
enough to enroll in a randomized trial, perhaps limiting
the sample of those inclined to change their self-report
because of mistrust.
The finding that those African Americans who are at
the highest level of comorbidity report better HRQOL
contrasts with studies of racial differences in HRQOL in
the general population and in other chronic disease states,
but is consistent with previous work on racial differences
in patient utilities [54]. For example, in the general popu-
lation, the National Center for Health Statistics reported
that non-Hispanic African Americans are less likely to
rate their health status as very good or excellent, when
compared with non-Hispanic whites (58.2% for African
American non-Hispanic persons, and 70.3% for white
non-Hispanic persons). Previous studies in other chronic
illnesses have found that whites report better HRQOL
than African Americans [55, 56]. In a comparison of
African American and white older male patients with
arthritis, African American ethnicity was negatively asso-
ciated with overall quality of life rating, after adjustment
for demographics, comorbidity, and psychologic param-
eters [56]. Patients’ utilities, which measure preferences
regarding states of health, are distinct from individuals’
reports of their experience, as measured by question-
naires assessing HRQOL. African Americans have been
found to assign higher levels of utility to relatively low
levels of functioning than whites [54]. Common under-
lying attitudes, perhaps related to expectations, may in-
fluence both these utilities and the report of relatively
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preserved quality of life in the face of severe comorbid
disease.
These results have important implications for health
care utilization and medical decision making. In previ-
ous studies, higher HRQOL has been associated with
longer survival [41]. Although no cause-and-effect rela-
tionship has been established, it is possible that the bet-
ter HRQOL of African Americans contributes to their
improved survival. It is also possible that racial differ-
ences in quality of life are related to racial differences
in the rates of voluntary dialysis discontinuation. It may
also be that better HRQOL on hemodialysis affects the
choice of renal replacement therapy and leads African
Americans to delay listing for transplantation. Few stud-
ies have examined the relationship of quality of life to
health care utilization, although data from studies in the
general population have shown a strong relationship be-
tween HRQOL and clinic visits and hospitalization [57].
Furthermore, the finding that HRQOL consistently de-
creased with increasing comorbidity emphasizes the im-
portance of targeting interventions to patients with the
highest comorbidity burden. Our results identify those
with the highest comorbidity as those with the most need
for interventions to improve HRQOL. Efforts to target
these high-risk individuals, through delivery of more in-
tensive health care services, may improve the physical
functioning and well being of these patients, in addition to
prolonging survival. However, the amount of variability
in HRQOL explained by demographic and laboratory
variables remains rather small, even when including
the level of comorbidity. This means that health care
providers need to make an effort to assess HRQOL by
self-report rather than by inference from laboratory data
and severity of comorbid illness.
The HEMO Study design overcame many of the limita-
tions of earlier reports regarding race and quality of life:
the study population was a large, multicenter hemodialy-
sis cohort, and the HRQOL instrument captured a multi-
dimensional concept of health. The analysis incorporated
extensive adjustment for demographic and socioeco-
nomic factors, as well as a validated index of comorbidity.
In addition, the HEMO Study employed the standard
technique for classification of race by using patient self-
identification of race and ethnicity. The study recapitu-
lated the findings of other reports on HRQOL in the
hemodialysis population: patients reported very impaired
physical well being, but mental aspects of health were less
affected [23, 24, 28].
Several limitations of this study should be considered
when interpreting our findings. First, this is a cross-
sectional analysis and suffers from the general limita-
tion of these analyses, such as a selection or survivorship
bias. However, the use of a comorbidity index and adjust-
ment for observed differences in covariates should limit
the impact of these biases. Second, our understanding
of differences in HRQOL by race is limited by the lack
of variables related to patients’ culture, life experience,
and attitudes about health, functioning, and expectations
about functioning. Further prospective data collection is
needed to understand the relationship of these factors
to our findings, and may lead to further understanding of
racial differences in HRQOL. Future studies of racial dif-
ferences in HRQOL should consider using instruments
such as the McGill Quality of Life questionnaire [58], or
the Missoula-Vitas instruments [59], both of which in-
clude spiritual/existential aspects in their assessment of
quality of life. Indeed, spirituality may play an additional
role beyond the dimensions measured by these instru-
ments, requiring new instrument development.
CONCLUSION
Improving the health-related quality of life of
hemodialysis patients is an important goal of hemodial-
ysis treatment. To our knowledge, chronic kidney failure
is the only chronic illness in which African Americans
report significantly better HRQOL than non-African
Americans. The persistent association of African Amer-
ican race with better physical functioning and fewer
dialysis-related symptoms and effects suggests either that
there are unmeasured differences between patients, or
that the race of the respondent influences perceived func-
tioning and well being at the highest level of comorbidity.
Future investigation should examine social, cultural, and
spiritual influences on the HRQOL of persons undergo-
ing hemodialysis. Clarification of the reasons for racial
differences may suggest measures to improve the qual-
ity of life for all patients receiving dialysis treatment for
chronic kidney failure.
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